| Year |
Citation |
Score |
| 2023 |
Luo Y, Shreeder B, Jenkins JW, Shi H, Lamichhane P, Zhou K, Bahr DA, Kurian S, Jones KA, Daum JI, Dutta N, Necela BM, Cannon MJ, Block MS, Knutson KL. Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade. Journal For Immunotherapy of Cancer. 11. PMID 37918918 DOI: 10.1136/jitc-2023-007661 |
0.362 |
|
| 2023 |
Carter JM, Chumsri S, Hinerfeld DA, Ma Y, Wang X, Zahrieh D, Hillman DW, Tenner KS, Kachergus JM, Brauer HA, Warren SE, Henderson D, Shi J, Liu Y, Joensuu H, ... ... Knutson KL, et al. Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. Nature Communications. 14: 2215. PMID 37072398 DOI: 10.1038/s41467-023-37806-0 |
0.338 |
|
| 2022 |
Ogony J, Hoskin TL, Stallings-Mann M, Winham S, Brahmbhatt R, Arshad MA, Kannan N, Peña A, Allers T, Brown A, Sherman ME, Visscher DW, Knutson KL, Radisky DC, Degnim AC. Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers. Breast Cancer Research and Treatment. PMID 36380012 DOI: 10.1007/s10549-022-06786-y |
0.345 |
|
| 2022 |
Sammons S, Raskina K, Danziger N, Alder L, Schrock AB, Venstrom JM, Knutson KL, Thompson EA, McGregor K, Sokol E, Chumsri S. APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy. Jco Precision Oncology. 6: e2200149. PMID 36315915 DOI: 10.1200/PO.22.00149 |
0.322 |
|
| 2022 |
Vivekanandhan S, Knutson KL. Resistance to Trastuzumab. Cancers. 14. PMID 36291900 DOI: 10.3390/cancers14205115 |
0.337 |
|
| 2020 |
Block MS, Dietz AB, Gustafson MP, Kalli KR, Erskine CL, Youssef B, Vijay GV, Allred JB, Pavelko KD, Strausbauch MA, Lin Y, Grudem ME, Jatoi A, Klampe CM, Wahner-Hendrickson AE, ... ... Knutson KL, et al. Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. Nature Communications. 11: 5173. PMID 33057068 DOI: 10.1038/s41467-020-18962-z |
0.32 |
|
| 2020 |
Gabriel EM, Kim M, Fisher DT, Powers C, Attwood K, Bagaria SP, Knutson KL, Skitzki JJ. Dynamic control of tumor vasculature improves antitumor responses in a regional model of melanoma. Scientific Reports. 10: 13245. PMID 32764623 DOI: 10.1038/S41598-020-70233-5 |
0.345 |
|
| 2020 |
Ogony JW, Radisky DC, Ruddy KJ, Goodison S, Wickland DP, Egan KM, Knutson KL, Asmann YW, Sherman ME. Immune Responses and Risk of Triple Negative Breast Cancer: Implications for Higher Rates among African American women. Cancer Prevention Research (Philadelphia, Pa.). PMID 32753376 DOI: 10.1158/1940-6207.Capr-19-0562 |
0.451 |
|
| 2020 |
Ren Y, Cherukuri Y, Wickland DP, Sarangi V, Tian S, Carter JM, Mansfield AS, Block MS, Sherman ME, Knutson KL, Lin Y, Asmann YW. HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. Oncoimmunology. 9: 1744947. PMID 32523802 DOI: 10.1080/2162402X.2020.1744947 |
0.478 |
|
| 2020 |
Zamarin D, Walderich S, Holland A, Zhou Q, Iasonos AE, Torrisi JM, Merghoub T, Chesebrough LF, Mcdonnell AS, Gallagher JM, Li Y, Hollmann TJ, Grisham RN, Erskine CL, Block MS, ... Knutson KL, et al. Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. Journal For Immunotherapy of Cancer. 8. PMID 32503949 DOI: 10.1136/Jitc-2020-000829 |
0.359 |
|
| 2020 |
Manna A, Kellett T, Aulakh S, Lewis-Tuffin LJ, Dutta N, Knutson K, Chini E, Pinilla-Ibarz J, Lamanna N, Manochakian R, Malavasi F, Sher T, Chanan-Khan AA, Ailawadhi S, Paulus A. Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses. Blood Advances. 4: 2143-2157. PMID 32421811 DOI: 10.1182/Bloodadvances.2019001091 |
0.389 |
|
| 2020 |
Adhikary S, Hoskin TL, Stallings-Mann ML, Arshad M, Frost MH, Winham SJ, Peña A, Lee DJ, Murphy LM, Rakoff M, Denison LA, Knutson KL, Radisky DC, Visscher DW, Degnim AC. Cytotoxic T cell depletion with increasing epithelial abnormality in women with benign breast disease. Breast Cancer Research and Treatment. PMID 31933142 DOI: 10.1007/S10549-019-05493-5 |
0.459 |
|
| 2020 |
Davis JM, Crowson CS, Knutson KL, Achenbach SJ, Strausbauch MA, Therneau TM, Matteson EL, Gabriel SE, Wettstein PJ. Longitudinal relationships between rheumatoid factor and cytokine expression by immunostimulated peripheral blood lymphocytes from patients with rheumatoid arthritis: New insights into B-cell activation. Clinical Immunology (Orlando, Fla.). 108342. PMID 31926330 DOI: 10.1016/J.Clim.2020.108342 |
0.336 |
|
| 2020 |
Chumsri S, Polley M, Mathur P, Reis A, Tenner KS, Weidner M, Advani P, Moreno-Aspitia A, Perez EA, Knutson KL. Phase I results of the phase I/II study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer. Journal of Clinical Oncology. 38: 78-78. DOI: 10.1200/Jco.2020.38.5_Suppl.78 |
0.308 |
|
| 2020 |
Leon-Ferre RA, McGrath K, Suman VJ, Carter JM, Kalari KR, Weinshilboum RM, Wang L, Ingle JN, Knutson KL, Ansell SM, Boughey JC, Villasboas JC, Goetz MP. Liquid biopsy of the immune environment: Evaluation of peripheral blood mononuclear cells (PBMCs) with CyTOF and response to trastuzumab (T)-based neoadjuvant chemotherapy (NAC) in HER2+ breast cancer (BC). Journal of Clinical Oncology. 38: 592-592. DOI: 10.1200/Jco.2020.38.15_Suppl.592 |
0.468 |
|
| 2020 |
Chumsri S, Carter JM, Ma Y, Hinerfeld D, Brauer HA, Warren S, Nielsen TO, Asleh K, Joensuu H, Perez EA, Leon-Ferre RA, Hillman DW, Boughey JC, Liu MC, Ingle JN, ... ... Knutson KL, et al. Role of intratumoral NK cells in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort. Journal of Clinical Oncology. 38: 510-510. DOI: 10.1200/Jco.2020.38.15_Suppl.510 |
0.446 |
|
| 2020 |
Degnim A, Vierkant R, Winham S, Frost M, Visscher D, Carter J, Kaggal S, Cunningham J, Allers T, Hoskin T, Heinzen E, Vachon C, Knutson K, Radisky D, Sherman M. Abstract P5-08-06: NSAID use and breast cancer risk in a retrospective cohort of women with benign breast disease Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-08-06 |
0.343 |
|
| 2020 |
Leon-Ferre RA, McGrath K, Carter JM, Kalari KR, Suman VJ, Weinshilboum R, Wang L, Knutson KL, Ansell SM, Boughey JC, Villasboas JC, Goetz MP. Abstract P5-04-09: Deep phenotyping using CyTOF identifies peripheral blood immune signatures associated with clinical outcomes and molecular subtypes in patients with early-stage triple negative breast cancer (TNBC) Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P5-04-09 |
0.426 |
|
| 2019 |
Knutson KL, Block MS, Norton N, Erskine CL, Hobday TJ, Dietz AB, Padley D, Gustafson MP, Puglisi-Knutson D, Mangskau TK, Chumsri S, Dueck AC, Karyampudi L, Wilson G, Degnim AC. Rapid generation of sustainable HER2-specific T cell immunity in HER2 breast cancer patients using a degenerate HLA class II epitope vaccine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31757875 DOI: 10.1158/1078-0432.Ccr-19-2123 |
0.519 |
|
| 2019 |
Lou Y, Marin-Acevedo JA, Vishnu P, Manochakian R, Dholaria B, Soyano A, Luo Y, Zhang Y, Knutson KL. Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. Immunotherapy. 11: 577-584. PMID 30943864 DOI: 10.2217/Imt-2018-0128 |
0.399 |
|
| 2019 |
Chumsri S, Serie DJ, Li Z, Pogue-Geile KL, Soyano A, Mashadi-Hossein A, Warren SE, Lou Y, Colon-Otero G, Knutson KL, Perez EA, Moreno-Aspitia A, Thompson EA. Effects of Age and Immune Landscape on Outcome in HER2-positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30808774 DOI: 10.1158/1078-0432.Ccr-18-2206 |
0.403 |
|
| 2019 |
Cannon MJ, Block MS, Morehead LC, Knutson KL. The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy. Immunotherapy. 11: 75-79. PMID 30730268 DOI: 10.2217/Imt-2018-0129 |
0.393 |
|
| 2019 |
Nordstrom JL, Muth J, Erskine CL, Sanders C, Yusko EC, Emerson RO, Lee M, Lee S, Trepel JB, Im S, Bang Y, Giaccone G, Bauer TM, Burris HA, Baughman JE, ... ... Knutson KL, et al. High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb). Journal of Clinical Oncology. 37: 1030-1030. DOI: 10.1200/Jco.2019.37.15_Suppl.1030 |
0.452 |
|
| 2019 |
Hinerfeld D, Knutson K, Radisky D, Thompson EA, Asmann Y, McCoy K, Degnim A, Carter J, Winham S, Cote M, Laak Jvd, Sherman M. Abstract 651: Analysis of the immune microenvironment to advance breast cancer risk prediction and prevention Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-651 |
0.434 |
|
| 2019 |
Luo Y, Barath S, Bahr DA, Dutta N, Raja G, Cannon MJ, Knutson KL. Abstract 1464: Inhibition of p38 MAPK in dendritic cells enhances their antigen presentation and induces Th17 T cell differentiation Cancer Research. 79: 1464-1464. DOI: 10.1158/1538-7445.Am2019-1464 |
0.436 |
|
| 2019 |
Park H, Uronis H, Kang Y, Ng M, Enzinger P, Lee K, Rutella S, Church S, Nordstrom J, Knutson K, Erskine C, Wu T, Yen J, Franovic A, Muth J, et al. Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T) Annals of Oncology. 30: v485. DOI: 10.1093/Annonc/Mdz253.015 |
0.322 |
|
| 2018 |
Soyano AE, Dholaria B, Marin-Acevedo JA, Diehl N, Hodge D, Luo Y, Manochakian R, Chumsri S, Adjei A, Knutson KL, Lou Y. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. Journal For Immunotherapy of Cancer. 6: 129. PMID 30470260 DOI: 10.1186/S40425-018-0447-2 |
0.31 |
|
| 2018 |
Norton N, Fox N, McCarl CA, Tenner KS, Ballman K, Erskine CL, Necela BM, Northfelt D, Tan WW, Calfa C, Pegram M, Colon-Otero G, Perez EA, Clynes R, Knutson KL. Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. Breast Cancer Research : Bcr. 20: 52. PMID 29898752 DOI: 10.1186/S13058-018-0989-8 |
0.43 |
|
| 2018 |
Kalli KR, Block MS, Kasi PM, Erskine CL, Hobday TJ, Dietz A, Padley D, Gustafson MP, Shreeder B, Puglisi-Knutson D, Visscher DW, Mangskau TK, Wilson G, Knutson KL. Folate Receptor Alpha Peptide Vaccine generates immunity in Breast and Ovarian Cancer Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29545464 DOI: 10.1158/1078-0432.Ccr-17-2499 |
0.483 |
|
| 2018 |
Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. Journal of Hematology & Oncology. 11: 39. PMID 29544515 DOI: 10.1186/S13045-018-0582-8 |
0.449 |
|
| 2018 |
Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y. Cancer immunotherapy beyond immune checkpoint inhibitors. Journal of Hematology & Oncology. 11: 8. PMID 29329556 DOI: 10.1186/S13045-017-0552-6 |
0.514 |
|
| 2018 |
Chumsri S, Polley M, Anderson SL, O'Sullivan CCM, Colon-Otero G, Knutson KL, Thompson EA, Moreno-Aspitia A. Phase I/II trial of pembrolizumab in combination with binimetinib in unresectable locally advanced or metastatic triple negative breast cancer. Journal of Clinical Oncology. 36: TPS17-TPS17. DOI: 10.1200/Jco.2018.36.5_Suppl.Tps17 |
0.455 |
|
| 2017 |
Carter JM, Hoskin TL, Pena MA, Brahmbhatt R, Winham SJ, Frost MH, Stallings-Mann M, Radisky DC, Knutson KL, Visscher DW, Degnim AC. Macrophagic "crown-like structures" are associated with an increased risk of breast cancer in benign breast disease. Cancer Prevention Research (Philadelphia, Pa.). PMID 29167285 DOI: 10.1158/1940-6207.Capr-17-0245 |
0.4 |
|
| 2017 |
Henle AM, Nassar A, Puglisi-Knutson D, Youssef B, Knutson KL. Downregulation of TAP1 and TAP2 in early stage breast cancer. Plos One. 12: e0187323. PMID 29091951 DOI: 10.1371/Journal.Pone.0187323 |
0.783 |
|
| 2017 |
Kerekes D, Visscher DW, Hoskin TL, Radisky DC, Brahmbhatt RD, Pena A, Frost MH, Arshad M, Stallings-Mann M, Winham SJ, Murphy L, Denison L, Carter JM, Knutson KL, Degnim AC. CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes. Breast Cancer Research and Treatment. PMID 29090365 DOI: 10.1007/S10549-017-4558-0 |
0.44 |
|
| 2017 |
Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Daum J, Kalli KR, Goode EL, Block MS, Cannon MJ, Knutson KL. IL-10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer. Cancer Research. PMID 28993412 DOI: 10.1158/0008-5472.Can-17-0740 |
0.348 |
|
| 2017 |
Yuan H, Jiang W, von Roemeling CA, Qie Y, Liu X, Chen Y, Wang Y, Wharen RE, Yun K, Bu G, Knutson KL, Kim BYS. Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. Nature Nanotechnology. PMID 28459470 DOI: 10.1038/Nnano.2017.69 |
0.424 |
|
| 2017 |
Degnim AC, Hoskin TL, Arshad M, Frost MH, Winham SJ, Brahmbhatt R, Pena A, Carter JM, Stallings-Mann M, Murphy L, Miller E, Denison L, Vachon CM, Knutson KL, Radisky DC, et al. Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28126725 DOI: 10.1158/1078-0432.Ccr-16-2026 |
0.481 |
|
| 2017 |
Soyano AE, Serie D, Mashadi-Hossein A, Warren S, Colon-Otero G, Knutson KL, Perez EA, Moreno-Aspitia A, Thompson EA, Chumsri S. Effects of age, immune landscape, and response to trastuzumab (H) in HER-2 positive (HER2+) breast cancer in NCCTG (Alliance)-N9831. Journal of Clinical Oncology. 35: 530-530. DOI: 10.1200/Jco.2017.35.15_Suppl.530 |
0.426 |
|
| 2017 |
Chumsri S, Serie DJ, Mashadi-Hossein A, Warren S, Moreno-Aspitia A, Colon-Otero G, Knutson KL, Perez EA, Thompson EA. Abstract 1682: Correlation of immune co-stimulatory molecule OX40 and outcome in trastuzumab treated HER2-positive breast cancer patients in the NCCTG-N9831 Cancer Research. 77: 1682-1682. DOI: 10.1158/1538-7445.Am2017-1682 |
0.47 |
|
| 2017 |
Soyano A, Dholaria B, Marin J, Diehl N, Hodge D, Luo Y, Yang L, Adjei A, Knutson K, Lou Y. P1.07-039 Blood Biomarkers Correlate with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti PD-1 Antibodies Journal of Thoracic Oncology. 12: S2011. DOI: 10.1016/J.Jtho.2017.09.958 |
0.318 |
|
| 2016 |
Cannioto RA, Sucheston-Campbell LE, Hampras S, Goode EL, Knutson K, Ness R, Modugno F, Wallace PK, Szender JB, Mayor P, Hong CC, Joseph JM, Friel G, Davis W, Nesline M, et al. The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 27759594 DOI: 10.1097/Igc.0000000000000845 |
0.424 |
|
| 2016 |
Hampras SS, Sucheston-Campbell LE, Cannioto R, Chang-Claude J, Modugno F, Dörk T, Hillemanns P, Preus L, Knutson KL, Wallace PK, Hong CC, Friel G, Davis W, Nesline M, Pearce CL, et al. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget. PMID 27533245 DOI: 10.18632/Oncotarget.10215 |
0.464 |
|
| 2016 |
Hieken TJ, Chen J, Hoskin TL, Walther-Antonio M, Johnson S, Ramaker S, Xiao J, Radisky DC, Knutson KL, Kalari KR, Yao JZ, Baddour LM, Chia N, Degnim AC. The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease. Scientific Reports. 6: 30751. PMID 27485780 DOI: 10.1038/Srep30751 |
0.391 |
|
| 2016 |
Knutson KL, Karyampudi L, Lamichhane P, Preston C. Retraction Note: Targeted immune therapy of ovarian cancer. Cancer Metastasis Reviews. PMID 27239671 DOI: 10.1007/S10555-016-9627-Z |
0.385 |
|
| 2016 |
Knutson KL, Clynes R, Shreeder B, Yeramian P, Kemp K, Ballman K, Tenner KS, Erskine CL, Norton N, Northfelt DW, Tan W, Calfa C, Pegram MD, Mittendorf EA, Perez EA. Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain. Cancer Research. PMID 27197192 DOI: 10.1158/0008-5472.Can-15-3091 |
0.422 |
|
| 2016 |
Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Block M, Knutson K. Abstract B66: Blockade of PD-1 signaling in tumor-associated dendritic cells results in compensatory IL-10 release maintaining immune suppression in ovarian cancer microenvironments. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B66 |
0.368 |
|
| 2016 |
Knutson K, Kalli K, Hobday T, Padley D, Erskine C, Dockter T, Suman V, Wilson G, Degnim A. Abstract P2-11-02: Robust generation of T cell immunity to HER2 in HER2+ breast cancer patients with a degenerate subdominant HLA-DR epitope vaccine Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P2-11-02 |
0.489 |
|
| 2015 |
Karyampudi L, Lamichhane P, Krempski J, Kalli KR, Behrens MD, Vargas DM, Hartmann LC, Janco JM, Dong H, Hedin KE, Dietz AB, Goode EL, Knutson KL. PD-1 blunts the function of ovarian tumor-infiltrating dendritic cells by inactivating NF-KappaB. Cancer Research. PMID 26567141 DOI: 10.1158/0008-5472.Can-15-0748 |
0.382 |
|
| 2015 |
Knutson KL, Mittendorf EA. Cancer vaccines in the new era of cancer immunotherapy. Vaccine. 33: 7376. PMID 26432907 DOI: 10.1016/J.Vaccine.2015.09.086 |
0.378 |
|
| 2015 |
Knutson KL, Maurer MJ, Preston CC, Moysich KB, Goergen K, Hawthorne KM, Cunningham JM, Odunsi K, Hartmann LC, Kalli KR, Oberg AL, Goode EL. Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. Cancer Immunology, Immunotherapy : Cii. PMID 26298430 DOI: 10.1007/S00262-015-1753-X |
0.464 |
|
| 2015 |
Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL. Tumor-infiltrating dendritic cells in cancer pathogenesis. Journal of Immunology (Baltimore, Md. : 1950). 194: 2985-91. PMID 25795789 DOI: 10.4049/Jimmunol.1403134 |
0.504 |
|
| 2015 |
Block MS, Maurer MJ, Goergen K, Kalli KR, Erskine CL, Behrens MD, Oberg AL, Knutson KL. Plasma immune analytes in patients with epithelial ovarian cancer. Cytokine. 73: 108-13. PMID 25743245 DOI: 10.1016/J.Cyto.2015.01.035 |
0.353 |
|
| 2015 |
Knutson KL, Karyampudi L, Lamichhane P, Preston C. Targeted immune therapy of ovarian cancer. Cancer Metastasis Reviews. 34: 53-74. PMID 25544369 DOI: 10.1007/S10555-014-9540-2 |
0.482 |
|
| 2015 |
Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P, Long HJ, Oberg A, Aderca I, Block MS, Bakkum-Gamez J, Federspiel MJ, Russell SJ, Kalli KR, et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Research. 75: 22-30. PMID 25398436 DOI: 10.1158/0008-5472.Can-14-2533 |
0.481 |
|
| 2015 |
Arshad MA, Visscher DW, Hoskin TL, Brahmbhatt RD, Pena Jimenez A, Frost MH, Miller EE, Stallings-Mann M, Murphy L, Winham SJ, Carter JM, Radisky DC, Knutson KL, Degnim AC. Quantitation of CD11c+ dendritic cells normal breast tissue and benign breast disease. Journal of Clinical Oncology. 33: e22115-e22115. DOI: 10.1200/Jco.2015.33.15_Suppl.E22115 |
0.407 |
|
| 2015 |
Kasi PM, Kalli K, Block MS, Hobday TJ, Dockter TJ, Suman VJ, Erskine CL, Visscher DW, Wilson G, Shreeder B, Knutson KL. A phase I trial of the safety and immunogenicity of a multi-epitope folate receptor alpha peptide vaccine used in combination with cyclophosphamide in subjects previously treated for breast or ovarian cancer. Journal of Clinical Oncology. 33: e14028-e14028. DOI: 10.1200/Jco.2015.33.15_Suppl.E14028 |
0.435 |
|
| 2015 |
Knutson KL, Clynes RA, Yeramian P, Kemp KP, Shreeder B, Ballman KV, Tenner KS, Erskine CL, Norton N, Northfelt DW, Tan W, Pegram MD, Calfa CJ, Mittendorf EA, Perez EA. Associations of HER2-specific immunity with survival during treatment with trastuzumab and chemotherapy in breast cancer. Journal of Clinical Oncology. 33: 587-587. DOI: 10.1200/Jco.2015.33.15_Suppl.587 |
0.495 |
|
| 2015 |
Brahmbhatt RD, Kerekes D, Hoskin TL, Pena A, Visscher DW, Stallings-Mann ML, Radisky DC, Murphy LM, Pankratz VS, Knutson KL, Frost M, Degnim AC. Abstract B34: CD56+ immune cell infiltration is decreased in benign breast lobules with fibrocystic changes Cancer Prevention Research. 8. DOI: 10.1158/1940-6215.Prev-14-B34 |
0.434 |
|
| 2015 |
Karyampudi L, Krempski J, Lamichhane P, Kalli KR, Behrens MD, Vargas DM, Hartmann LC, Hedin KE, Goode EL, Knutson KL. Abstract POSTER-THER-1418: PD-1 mediated paralysis of ovarian cancer infiltrating dendritic cells Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ther-1418 |
0.411 |
|
| 2015 |
Arshad MA, Visscher DW, Hoskin TL, Brahmbhatt RD, Jimenez AP, Mann MLS, Miller EE, Murphy LM, Carter JM, Winham SJ, Knutson KL, Radisky DC, Degnim AC. Abstract 2364: CD68+ immune cells show different infiltration patterns in tissue samples from women with no clinical breast disease and those who have benign breast disease Cancer Research. 75: 2364-2364. DOI: 10.1158/1538-7445.Am2015-2364 |
0.42 |
|
| 2014 |
Norton N, Olson RM, Pegram M, Tenner K, Ballman KV, Clynes R, Knutson KL, Perez EA. Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831. Cancer Immunology Research. 2: 962-9. PMID 24989892 DOI: 10.1158/2326-6066.Cir-14-0059 |
0.338 |
|
| 2014 |
Charbonneau B, Moysich KB, Kalli KR, Oberg AL, Vierkant RA, Fogarty ZC, Block MS, Maurer MJ, Goergen KM, Fridley BL, Cunningham JM, Rider DN, Preston C, Hartmann LC, Lawrenson K, ... ... Knutson KL, et al. Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. Cancer Immunology Research. 2: 332-40. PMID 24764580 DOI: 10.1158/2326-6066.Cir-13-0136 |
0.361 |
|
| 2014 |
Block MS, Charbonneau B, Vierkant RA, Fogarty Z, Bamlet WR, Pharoah PD, Rossing MA, Cramer D, Pearce CL, Schildkraut J, Menon U, Kjaer SK, ... ... Knutson KL, et al. Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 1421-7. PMID 24740199 DOI: 10.1158/1055-9965.Epi-13-0962 |
0.383 |
|
| 2014 |
Karyampudi L, Lamichhane P, Scheid AD, Kalli KR, Shreeder B, Krempski JW, Behrens MD, Knutson KL. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Research. 74: 2974-85. PMID 24728077 DOI: 10.1158/0008-5472.Can-13-2564 |
0.492 |
|
| 2014 |
Wang C, Cicek MS, Charbonneau B, Kalli KR, Armasu SM, Larson MC, Konecny GE, Winterhoff B, Fan JB, Bibikova M, Chien J, Shridhar V, Block MS, Hartmann LC, Visscher DW, ... ... Knutson KL, et al. Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer. Cancer Research. 74: 3084-91. PMID 24728075 DOI: 10.1158/0008-5472.Can-13-3198 |
0.446 |
|
| 2014 |
Degnim AC, Brahmbhatt RD, Radisky DC, Hoskin TL, Stallings-Mann M, Laudenschlager M, Mansfield A, Frost MH, Murphy L, Knutson K, Visscher DW. Immune cell quantitation in normal breast tissue lobules with and without lobulitis. Breast Cancer Research and Treatment. 144: 539-49. PMID 24596048 DOI: 10.1007/S10549-014-2896-8 |
0.439 |
|
| 2014 |
Charbonneau B, Block MS, Bamlet WR, Vierkant RA, Kalli KR, Fogarty Z, Rider DN, Sellers TA, Tworoger SS, Poole E, Risch HA, Salvesen HB, Kiemeney LA, Baglietto L, Giles GG, ... ... Knutson KL, et al. Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10. Cancer Research. 74: 852-61. PMID 24272484 DOI: 10.1158/0008-5472.Can-13-1051 |
0.354 |
|
| 2014 |
Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene. 33: 1316-24. PMID 23474758 DOI: 10.1038/Onc.2013.57 |
0.461 |
|
| 2014 |
Block MS, Maurer MJ, Goergen K, Kalli KR, Erskine CL, Behrens MD, Knutson KL. Abstract 1873: Plasma heat shock protein 90kDa beta member 1 levels predict both early stage and advanced stage ovarian cancer independently from cancer antigen 125 in patients with an indeterminate adnexal mass Cancer Research. 74: 1873-1873. DOI: 10.1158/1538-7445.Am2014-1873 |
0.339 |
|
| 2013 |
Davis JM, Knutson KL, Strausbauch MA, Green AB, Crowson CS, Therneau TM, Matteson EL, Gabriel SE. Immune response profiling in early rheumatoid arthritis: discovery of a novel interaction of treatment response with viral immunity. Arthritis Research & Therapy. 15: R199. PMID 24267267 DOI: 10.1186/Ar4389 |
0.302 |
|
| 2013 |
Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, Goode EL, Knutson KL. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. Plos One. 8: e80063. PMID 24244610 DOI: 10.1371/Journal.Pone.0080063 |
0.353 |
|
| 2013 |
Derycke MS, Charbonneau B, Preston CC, Kalli KR, Knutson KL, Rider DN, Goode EL. Toward understanding the genetics of regulatory T cells in ovarian cancer. Oncoimmunology. 2: e24535. PMID 23894717 DOI: 10.4161/Onci.24535 |
0.494 |
|
| 2013 |
Carlson AM, Maurer MJ, Goergen KM, Kalli KR, Erskine CL, Behrens MD, Knutson KL, Block MS. Utility of progranulin and serum leukocyte protease inhibitor as diagnostic and prognostic biomarkers in ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 22: 1730-5. PMID 23878295 DOI: 10.1158/1055-9965.Epi-12-1368 |
0.327 |
|
| 2013 |
Charbonneau B, Goode EL, Kalli KR, Knutson KL, Derycke MS. The immune system in the pathogenesis of ovarian cancer. Critical Reviews in Immunology. 33: 137-64. PMID 23582060 DOI: 10.1615/Critrevimmunol.2013006813 |
0.481 |
|
| 2013 |
Pavelko KD, Bell MP, Karyampudi L, Hansen MJ, Allen KS, Knutson KL, Pease LR. The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1087-95. PMID 23568262 DOI: 10.1038/Mt.2013.52 |
0.431 |
|
| 2013 |
Goode EL, DeRycke M, Kalli KR, Oberg AL, Cunningham JM, Maurer MJ, Fridley BL, Armasu SM, Serie DJ, Ramar P, Goergen K, Vierkant RA, Rider DN, Sicotte H, Wang C, ... ... Knutson KL, et al. Inherited variants in regulatory T cell genes and outcome of ovarian cancer. Plos One. 8: e53903. PMID 23382860 DOI: 10.1371/Journal.Pone.0053903 |
0.389 |
|
| 2013 |
Mader EK, Butler G, Dowdy SC, Mariani A, Knutson KL, Federspiel MJ, Russell SJ, Galanis E, Dietz AB, Peng KW. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. Journal of Translational Medicine. 11: 20. PMID 23347343 DOI: 10.1186/1479-5876-11-20 |
0.383 |
|
| 2013 |
Henle AM, Erskine CL, Benson LM, Clynes R, Knutson KL. Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells. Journal of Immunology (Baltimore, Md. : 1950). 190: 479-88. PMID 23180824 DOI: 10.4049/Jimmunol.1201264 |
0.775 |
|
| 2013 |
Knutson KL, Perez EA, Ballman KV, Erskine CL, Fox N, McCarl C, Norton N, Sumrall SV, Northfelt DW, Tan W, Calfa CJ, Pegram MD, Clynes R. Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831. Journal of Clinical Oncology. 31: 522-522. DOI: 10.1200/Jco.2013.31.15_Suppl.522 |
0.406 |
|
| 2013 |
Clynes R, Knutson KL, Ballman KV, Erskine CL, Norton N, Sumrall SV, Northfelt DW, Tan W, Calfa CJ, Pegram MD, Perez EA. Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52. Journal of Clinical Oncology. 31: 521-521. DOI: 10.1200/Jco.2013.31.15_Suppl.521 |
0.496 |
|
| 2013 |
Pegram M, Olson RM, Norton N, Tenner K, Ballman KL, Clynes R, Knutson KL, Perez EA. Abstract B123: Analysis of the associations of FC gamma receptor polymorphisms (FCGR3A, FCGR2A, and FCGR2B) with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) trial N9831 Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-B123 |
0.394 |
|
| 2013 |
Asiedu MK, Beauchamp-Perez F, Ingle JN, Behrens MD, Radisky DC, Knutson K. Abstract LB-272: AXL induces epithelial to mesenchymal transition and regulates the function of breast cancer stem cells. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-272 |
0.483 |
|
| 2013 |
Charbonneau B, Knutson K, Vierkant RA, Cunningham JM, Fogarty ZC, Kalli KR, Maurer MJ, Oberg AL, Fridley BL, Preston CC, Pharoah PDP, Ramus SJ, Phelan CM, Odunsi K, Moysich K, et al. Abstract 4844: Polymorphisms in regulatory T cell related genes and ovarian cancer survival. Cancer Research. 73: 4844-4844. DOI: 10.1158/1538-7445.Am2013-4844 |
0.387 |
|
| 2013 |
Block MS, Maurer MJ, Goergen KM, Erskine CL, Behrens MD, Kalli KR, Knutson KL. Abstract 3476: Higher plasma levels of heparan sulfate are associated with improved survival of patients with advanced ovarian cancer. Cancer Research. 73: 3476-3476. DOI: 10.1158/1538-7445.Am2013-3476 |
0.387 |
|
| 2013 |
Kalli KR, Erskine CL, Krempski JW, Benson LM, Suman VJ, Padley DJ, Dietz AB, Hobday TJ, Degnim AC, Hartmann LC, Block MS, Knutson KL. Abstract A82: Metronomic cyclophosphamide followed by a multi-peptide folate receptor vaccine for ovarian and breast cancer immunotherapy in the setting of minimal residual disease - a feasibility study Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-A82 |
0.498 |
|
| 2013 |
Knutson KL, Radisky DC. The immune system in breast cancer initiation and progression: Role of epithelial to mesenchymal transition Cell and Molecular Biology of Breast Cancer. 43-64. DOI: 10.1007/978-1-62703-634-4_3 |
0.358 |
|
| 2012 |
Manjili MH, Egilmez N, Knutson KL, Selvan SR, Ostberg JR. Tumor escape and progression under immune pressure. Clinical & Developmental Immunology. 2012: 641079. PMID 23316254 DOI: 10.1155/2012/641079 |
0.525 |
|
| 2012 |
Erskine CL, Henle AM, Knutson KL. Determining optimal cytotoxic activity of human Her2neu specific CD8 T cells by comparing the Cr51 release assay to the xCELLigence system Journal of Visualized Experiments : Jove. e3683. PMID 22895471 DOI: 10.3791/3683 |
0.763 |
|
| 2012 |
Block MS, Maurer MJ, Ramar P, Behrens MD, Erskine CL, Kalli KR, Hartmann LC, Knutson KL. Abstract 1382: Increased expression of placental growth factor is linked with shortened survival of patients with advanced ovarian cancer Cancer Research. 72: 1382-1382. DOI: 10.1158/1538-7445.Am2012-1382 |
0.32 |
|
| 2011 |
Erskine CL, Krco CJ, Hedin KE, Borson ND, Kalli KR, Behrens MD, Heman-Ackah SM, von Hofe E, Wettstein PJ, Mohamadzadeh M, Knutson KL. MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells. Journal of Immunology (Baltimore, Md. : 1950). 187: 316-24. PMID 21613617 DOI: 10.4049/Jimmunol.1100658 |
0.428 |
|
| 2011 |
Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL. TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Research. 71: 4707-19. PMID 21555371 DOI: 10.1158/0008-5472.Can-10-4554 |
0.468 |
|
| 2011 |
Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. Journal of Immunology (Baltimore, Md. : 1950). 186: 6905-13. PMID 21551365 DOI: 10.4049/Jimmunol.1100274 |
0.471 |
|
| 2011 |
Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity and immune suppression in human ovarian cancer. Immunotherapy. 3: 539-56. PMID 21463194 DOI: 10.2217/Imt.11.20 |
0.477 |
|
| 2011 |
Wahner Hendrickson AE, Goode EL, Knutson KL, Kalli K, Ramar P, Hartmann LC, Maurer MJ. Predictors of ovarian cancer survival: A prospective study at Mayo Clinic. Journal of Clinical Oncology. 29: e15526-e15526. DOI: 10.1200/Jco.2011.29.15_Suppl.E15526 |
0.342 |
|
| 2011 |
Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL. Abstract 3341: TGFβ/ TNFα-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype Cancer Research. 71: 3341-3341. DOI: 10.1158/1538-7445.Am2011-3341 |
0.458 |
|
| 2011 |
Nakamura I, Asiedu MK, Knutson K, Ahmed KH, Moser CD, Hu C, Roberts LR. Decreased Liver Tumorigenesis in Sulfatase 2 (SULF2) Knockout Mice May Be Mediated Through Inhibition of the Epithelial-Mesenchymal Transition (EMT) Gastroenterology. 140: S-680. DOI: 10.1016/S0016-5085(11)62820-5 |
0.315 |
|
| 2010 |
Karyampudi L, Knutson KL. Antibodies in cancer immunotherapy. Cancer Biomarkers : Section a of Disease Markers. 6: 291-305. PMID 20938089 DOI: 10.3233/Cbm-2009-0141 |
0.365 |
|
| 2010 |
Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: A pilot clinical trial Journal of Translational Medicine. 8. PMID 20529245 DOI: 10.1186/1479-5876-8-53 |
0.442 |
|
| 2010 |
Davis JM, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Matteson EL, Gabriel SE. Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells. Journal of Immunology (Baltimore, Md. : 1950). 184: 7297-304. PMID 20495063 DOI: 10.4049/Jimmunol.0904180 |
0.321 |
|
| 2010 |
Radhakrishnan S, Wiehagen KR, Pulko V, Van Keulen V, Faubion WA, Knutson KL, Pease LR. Induction of a Th1 response from Th2-polarized T cells by activated dendritic cells: Dependence on TCR:Peptide-MHC interaction, ICAM-1, IL-12, and IFN-{gamma} (The Journal of Immunology (2007) 178, (3583-3592)) Journal of Immunology. 184: 6555. PMID 20483795 DOI: 10.4049/Jimmunol.1090034 |
0.325 |
|
| 2010 |
Reiman JM, Knutson KL, Radisky DC. Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells Cancer Research. 70: 3005-3008. PMID 20395197 DOI: 10.1158/0008-5472.Can-09-4041 |
0.819 |
|
| 2010 |
Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunology, Immunotherapy : Cii. 59: 943-53. PMID 20140431 DOI: 10.1007/S00262-010-0820-6 |
0.421 |
|
| 2010 |
Karyampudi L, Formicola C, Erskine CL, Maurer MJ, Ingle JN, Krco CJ, Wettstein PJ, Kalli KR, Fikes JD, Beebe M, Hartmann LC, Disis ML, Ferrone S, Ishioka G, Knutson KL. A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 825-34. PMID 20103660 DOI: 10.1158/1078-0432.Ccr-09-2781 |
0.429 |
|
| 2010 |
Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1-bone marrow progenitor cells into myeloid-derived suppressor cells Breast Cancer Research and Treatment. 123: 39-49. PMID 19898981 DOI: 10.1007/S10549-009-0622-8 |
0.506 |
|
| 2010 |
Karyampudi L, Krco CJ, Kalli KR, Erskine CL, Hartmann LC, Goodman K, Ingle JN, Maurer MJ, Nassar A, Yu C, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, ... Knutson KL, et al. Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. Cancer Immunology, Immunotherapy : Cii. 59: 161-71. PMID 19621224 DOI: 10.1007/S00262-009-0738-Z |
0.543 |
|
| 2010 |
Ding W, Maurer MJ, Kalli K, Murphy L, Hartmann LC, Knutson KL, Clayton AC. Prognostic role of dendritic cells and T lymphocytes in the clinical outcomes of stage III ovarian cancer. Journal of Clinical Oncology. 28: 5069-5069. DOI: 10.1200/Jco.2010.28.15_Suppl.5069 |
0.421 |
|
| 2010 |
Davis J, Knutson K, Matteson E, Strausbauch M, Crowson C, Gabriel S. Identification of a Multi-cytokine Immune Response Signature of Disease Activity in Rheumatoid Arthritis Clinical Immunology. 135: S77. DOI: 10.1016/J.Clim.2010.03.231 |
0.311 |
|
| 2009 |
Salazar LG, Goodell V, O'Meara M, Knutson K, Dang Y, Dela Rosa C, Guthrie KA, Disis ML. Persistent immunity and survival after immunization with a HER2/neu (HER2) vaccine. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3010. PMID 27962062 DOI: 10.1200/Jco.2009.27.15_Suppl.3010 |
0.446 |
|
| 2009 |
Basal E, Eghbali-Fatourechi GZ, Kalli KR, Hartmann LC, Goodman KM, Goode EL, Kamen BA, Low PS, Knutson KL. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. Plos One. 4: e6292. PMID 19617914 DOI: 10.1371/Journal.Pone.0006292 |
0.359 |
|
| 2009 |
Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon Carcinoma Gastroenterology. 137: 1270-1279. PMID 19577568 DOI: 10.1053/J.Gastro.2009.06.053 |
0.438 |
|
| 2009 |
Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S, Knutson KL. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Research. 69: 2887-95. PMID 19276366 DOI: 10.1158/0008-5472.Can-08-3343 |
0.815 |
|
| 2009 |
Sinicrope FA, Rego RL, Ansell S, Knutson K, Foster NR, Sargent DJ. W1883 Low Intraepithelial CD3+/FOXP3+ Regulatory T-Cell Ratio Predicts Adverse Outcome in Human Colon Carcinomas Gastroenterology. 136: A-746. DOI: 10.1016/S0016-5085(09)63442-9 |
0.314 |
|
| 2008 |
Gustafson MP, Knutson KL, Dietz AB. Therapeutic vaccines for malignant brain tumors. Biologics : Targets & Therapy. 2: 753-61. PMID 19707456 DOI: 10.2147/Btt.S3197 |
0.364 |
|
| 2008 |
Kalli KR, Krco CJ, Hartmann LC, Goodman K, Maurer MJ, Yu C, Johnson EM, Erskine CL, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, Knutson KL. An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. Cancer Research. 68: 4893-901. PMID 18559537 DOI: 10.1158/0008-5472.Can-07-6726 |
0.486 |
|
| 2008 |
Worschech A, Kmieciak M, Knutson KL, Bear HD, Szalay AA, Wang E, Marincola FM, Manjili MH. Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Research. 68: 2436-46. PMID 18381452 DOI: 10.1158/0008-5472.Can-07-6822 |
0.481 |
|
| 2008 |
Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecologic Oncology. 108: 619-26. PMID 18222534 DOI: 10.1016/J.Ygyno.2007.11.020 |
0.406 |
|
| 2008 |
Behrens MD, Wagner WM, Krco CJ, Erskine CL, Kalli KR, Krempski J, Gad EA, Disis ML, Knutson KL. The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood. 111: 1472-9. PMID 18029553 DOI: 10.1182/Blood-2007-10-117184 |
0.49 |
|
| 2008 |
Disis ML, Knutson KL. General approaches to measuring immune responses General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology. 393-404. DOI: 10.1007/978-1-4020-6087-8_17 |
0.362 |
|
| 2007 |
Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL, Clynes R. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5133-43. PMID 17785568 DOI: 10.1158/1078-0432.Ccr-07-0507 |
0.443 |
|
| 2007 |
Reiman JM, Kmieciak M, Manjili MH, Knutson KL. Tumor immunoediting and immunosculpting pathways to cancer progression Seminars in Cancer Biology. 17: 275-287. PMID 17662614 DOI: 10.1016/J.Semcancer.2007.06.009 |
0.8 |
|
| 2007 |
Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL, et al. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2075-81. PMID 17404089 DOI: 10.1158/1078-0432.Ccr-06-2139 |
0.445 |
|
| 2007 |
Dang Y, Knutson KL, Goodell V, Dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML. Tumor antigen - Specific T-cell expansion is greatly facilitated by in vivo priming Clinical Cancer Research. 13: 1883-1891. PMID 17363545 DOI: 10.1158/1078-0432.Ccr-06-2083 |
0.491 |
|
| 2007 |
Radhakrishnan S, Wiehagen KR, Pulko V, Van Keulen V, Faubion WA, Knutson KL, Pease LR. Induction of a Th1 response from Th2-polarized T cells by activated dendritic cells: dependence on TCR:peptide-MHC interaction, ICAM-1, IL-12, and IFN-gamma. Journal of Immunology (Baltimore, Md. : 1950). 178: 3583-92. PMID 17339455 DOI: 10.4049/Jimmunol.178.6.3583 |
0.368 |
|
| 2007 |
Kmieciak M, Knutson KL, Dumur CI, Manjili MH. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses European Journal of Immunology. 37: 675-685. PMID 17304628 DOI: 10.1002/Eji.200636639 |
0.502 |
|
| 2007 |
Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E. Peptide vaccine given with a toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors Cancer Research. 67: 1326-1334. PMID 17283170 DOI: 10.1158/0008-5472.Can-06-3290 |
0.491 |
|
| 2007 |
Knutson KL, Disis ML, Salazar LG. CD4 regulatory T cells in human cancer pathogenesis Cancer Immunology, Immunotherapy. 56: 271-285. PMID 16819631 DOI: 10.1007/S00262-006-0194-Y |
0.473 |
|
| 2007 |
Nava-Parada P, Herron A, Knutson KL, Pease L, Celis E. Breast cancer vaccines: maximizing peptide-based vaccines by regulatory T cell depletion and toll-like receptor 9 activation Bmc Cancer. 7. DOI: 10.1186/1471-2407-7-S1-A2 |
0.488 |
|
| 2006 |
Manjili MH, Arnouk H, Knutson KL, Kmieciak M, Disis ML, Subjeck JR, Kazim AL. Erratum to: Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". Breast Cancer Research and Treatment. 96: 243. PMID 28303485 DOI: 10.1007/S10549-006-9163-6 |
0.428 |
|
| 2006 |
Lu H, Knutson KL, Gad E, Disis ML. The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Research. 66: 9754-61. PMID 17018635 DOI: 10.1158/0008-5472.Can-06-1083 |
0.489 |
|
| 2006 |
Knutson KL, Krco CJ, Erskine CL, Goodman K, Kelemen LE, Wettstein PJ, Low PS, Hartmann LC, Kalli KR. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4254-61. PMID 16908932 DOI: 10.1200/Jco.2006.05.9311 |
0.501 |
|
| 2006 |
Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, Prosperi CM, Gad EA, Smorlesi A, Disis ML. Immunoediting of cancers may lead to epithelial to mesenchymal transition. Journal of Immunology (Baltimore, Md. : 1950). 177: 1526-33. PMID 16849459 DOI: 10.4049/Jimmunol.177.3.1526 |
0.804 |
|
| 2006 |
Knutson KL. Strong-arming immune regulation: Suppressing regulatory T-cell function to treat cancers Future Oncology. 2: 379-389. PMID 16787118 DOI: 10.2217/14796694.2.3.379 |
0.466 |
|
| 2006 |
Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, Azeke E, Disis ML. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 177: 84-91. PMID 16785502 DOI: 10.4049/Jimmunol.177.1.84 |
0.571 |
|
| 2006 |
Zhang H, Knutson KL, Hellstrom KE, Disis ML, Hellstrom I. Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion Molecular Cancer Therapeutics. 5: 149-155. PMID 16432173 DOI: 10.1158/1535-7163.Mct-05-0206 |
0.487 |
|
| 2006 |
Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Research. 66: 1147-54. PMID 16424052 DOI: 10.1158/0008-5472.Can-05-2289 |
0.473 |
|
| 2006 |
Knutson KL, Dela Rosa C, Disis ML. Laboratory analysis of T-cell immunity Frontiers in Bioscience. 11: 1932-1944. PMID 16368569 DOI: 10.2741/1936 |
0.484 |
|
| 2006 |
Manjili MH, Arnouk H, Knutson KL, Kmieciak M, Disis ML, Subjeck JR, Kazim AL. Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". Breast Cancer Research and Treatment. 96: 233-41. PMID 16211331 DOI: 10.1007/S10549-005-9044-4 |
0.516 |
|
| 2006 |
Knutson KL, Wagner W, Disis ML. Adoptive T cell therapy of solid cancers Cancer Immunology, Immunotherapy. 55: 96-103. PMID 15891880 DOI: 10.1007/S00262-005-0706-1 |
0.443 |
|
| 2006 |
Knutson KL, Kalli KR, Krco CJ, Goodman K, Kelemen LE, Low PS, Hartmann LC. Patients with breast and ovarian cancer generate immune responses to the folate receptor alpha Journal of Clinical Oncology. 24: 20043-20043. DOI: 10.1200/Jco.2006.24.18_Suppl.20043 |
0.54 |
|
| 2005 |
Knutson KL, Disis ML. Augmenting T helper cell immunity in cancer Current Drug Targets: Immune, Endocrine and Metabolic Disorders. 5: 365-371. PMID 16375690 DOI: 10.2174/156800805774913006 |
0.472 |
|
| 2005 |
Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy Cancer Immunology, Immunotherapy. 54: 721-728. PMID 16010587 DOI: 10.1007/S00262-004-0653-2 |
0.502 |
|
| 2005 |
Knutson KL, Prosperi C, Bronson J. TNF-Alpha Mediates Immune Editing of Breast Cancers by Inducing Epithelial to Mesenchymal Transition Journal of Immunotherapy. 28: 645-646. DOI: 10.1097/01.Cji.0000191055.81135.A5 |
0.411 |
|
| 2005 |
Wagner W, Krco C, Behrens M, Vielhauer G, Disis ML, Knutson KL. Uric Acid Elicits Anti-Tumor Humoral Immunity Without T Cell Expansion When Used As A Vaccine Adjuvant Journal of Immunotherapy. 28: 645. DOI: 10.1097/01.Cji.0000191054.81135.Ec |
0.458 |
|
| 2005 |
Knutson K, Dang Y, Hailing L, Lukas J, Almand B, Gad E, Azeke E, Disis ML. Induction of Therapeutic Breast Cancer Immunity With an IL-2 Immunotoxin Journal of Immunotherapy. 28: 640. DOI: 10.1097/01.Cji.0000191037.38072.08 |
0.424 |
|
| 2005 |
Knutson KL. Cancer vaccines: The next generation Drug Discovery Today: Therapeutic Strategies. 2: 323-330. DOI: 10.1016/J.Ddstr.2005.11.002 |
0.307 |
|
| 2004 |
Disis ML, Salazar LG, Knutson KL. Peptide-based vaccines in breast cancer Breast Disease. 20: 3-11. PMID 15687702 DOI: 10.3233/Bd-2004-20102 |
0.552 |
|
| 2004 |
Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral Epitope-Spreading Following Immunization with a HER-2/neu Peptide Based Vaccine in Cancer Patients Journal of Clinical Immunology. 24: 571-578. PMID 15359116 DOI: 10.1023/B:Joci.0000040928.67495.52 |
0.446 |
|
| 2004 |
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, ... ... Knutson KL, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine. 10: 942-9. PMID 15322536 DOI: 10.1038/Nm1093 |
0.504 |
|
| 2004 |
Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, Dela Rosa C, Cheever MA. Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein-based vaccine Journal of Clinical Oncology. 22: 1916-1925. PMID 15143085 DOI: 10.1200/Jco.2004.09.005 |
0.412 |
|
| 2004 |
Knutson KL, Almand B, Dang Y, Disis ML. neu Antigen-Negative Variants Can Be Generated after neu-Specific Antibody Therapy in neu Transgenic Mice Cancer Research. 64: 1146-1151. PMID 14871850 DOI: 10.1158/0008-5472.Can-03-0173 |
0.433 |
|
| 2004 |
Knutson KL, Disis ML. IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion Clinical and Experimental Immunology. 135: 322-329. PMID 14738463 DOI: 10.1111/j.1365-2249.2004.02360.x |
0.325 |
|
| 2004 |
Dang Y, Disis ML(, Gad E, Knutson K. Regulatory T Cells May Induce Tolerance Early in the Course of Tumor Development Journal of Immunotherapy. 27: S45. DOI: 10.1097/00002371-200411000-00163 |
0.441 |
|
| 2003 |
Knutson KL, Salazar L, Schiffman K, Disis ML. Immunotherapy of glioblastoma multiforme. Expert Review of Neurotherapeutics. 3: 511-23. PMID 19810935 DOI: 10.1586/14737175.3.4.511 |
0.458 |
|
| 2003 |
Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K, Disis ML. Immunization of Cancer Patients with HER-2/neu-Derived Peptides Demonstrating High-Affinity Binding to Multiple Class II Alleles Clinical Cancer Research. 9: 5559-5565. PMID 14654536 |
0.308 |
|
| 2003 |
Disis ML, Scholler N, Dahlin A, Pullman J, Knutson KL, Hellstrom̈ KE, Hellstrom̈ I. Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity Molecular Cancer Therapeutics. 2: 995-1002. PMID 14578464 |
0.352 |
|
| 2003 |
Knutson KL, Curiel TJ, Salazar L, Disis ML. Immunologic principles and immunotherapeutic approaches in ovarian cancer. Hematology/Oncology Clinics of North America. 17: 1051-73. PMID 12959191 DOI: 10.1016/S0889-8588(03)00064-9 |
0.508 |
|
| 2003 |
Disis ML, Shiota FM, McNeel DG, Knutson KL. Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens Immunobiology. 207: 179-186. PMID 12777059 DOI: 10.1078/0171-2985-00230 |
0.405 |
|
| 2003 |
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, Gordon A, Dhurandhar N, Myers L, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Medicine. 9: 562-7. PMID 12704383 DOI: 10.1038/Nm863 |
0.407 |
|
| 2003 |
McNeel DG, Knutson KL, Schiffman K, Davis DR, Caron D, Disis ML. Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. Journal of Clinical Immunology. 23: 62-72. PMID 12645861 DOI: 10.1023/A:1021904432489 |
0.361 |
|
| 2002 |
Knutson KL, Bishop MR, Schiffman K, Disis ML. Immunotherapy for breast cancer Cancer Chemotherapy and Biological Response Modifiers. 20: 351-369. PMID 12703214 |
0.306 |
|
| 2002 |
Knutson KL, Disis ML. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient Human Immunology. 63: 547-557. PMID 12072190 DOI: 10.1016/S0198-8859(02)00401-9 |
0.442 |
|
| 2002 |
Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 2624-32. PMID 12039923 DOI: 10.1200/Jco.2002.06.171 |
0.516 |
|
| 2002 |
Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity Clinical Cancer Research. 8: 1014-1018. PMID 12006513 |
0.35 |
|
| 2002 |
Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela Rosa C, Schiffman K. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood. 99: 2845-50. PMID 11929774 DOI: 10.1182/Blood.V99.8.2845 |
0.383 |
|
| 2002 |
Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML. Vaccination against the HER-2/neu oncogenic protein Endocrine-Related Cancer. 9: 33-44. PMID 11914181 DOI: 10.1677/Erc.0.0090033 |
0.536 |
|
| 2002 |
Knutson KL, Disis ML. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine. Clinical Breast Cancer. 2: 73-9. PMID 11899386 DOI: 10.3816/Cbc.2001.N.014 |
0.541 |
|
| 2002 |
Knutson KL, Almand B, Mankoff DA, Schiffman K, Disis ML. Adoptive T-cell therapy for the treatment of solid tumours Expert Opinion On Biological Therapy. 2: 55-66. PMID 11772340 DOI: 10.1517/14712598.2.1.55 |
0.386 |
|
| 2001 |
Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients Journal of Clinical Investigation. 107: 477-484. PMID 11181647 DOI: 10.1172/Jci11752 |
0.456 |
|
| 2001 |
Disis ML, Knutson KL, McNeel DG, Davis D, Schiffman K. Clinical Translation of Peptide-Based Vaccine Trials: The HER-2/neu Model Critical Reviews™ in Immunology. 21: 11. DOI: 10.1615/Critrevimmunol.V21.I1-3.170 |
0.497 |
|
| 2000 |
Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer Breast Cancer Research and Treatment. 62: 245-252. PMID 11072789 DOI: 10.1023/A:1006438507898 |
0.549 |
|
| 1999 |
Knutson KL, Schiffman K, Rinn K, Disis ML. Immunotherapeutic Approaches for the Treatment of Breast Cancer Journal of Mammary Gland Biology and Neoplasia. 4: 353-365. PMID 10705919 DOI: 10.1023/A:1018714300217 |
0.545 |
|
| Show low-probability matches. |